438 related articles for article (PubMed ID: 31572678)
21. A New Era of Immunotherapy in Prostate Cancer.
Pizzola C; Rizvi SM; Joshi M
Curr Mol Pharmacol; 2016; 9(3):217-225. PubMed ID: 26177645
[TBL] [Abstract][Full Text] [Related]
22. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
23. Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer.
Ollivier L; Labbé M; Fradin D; Potiron V; Supiot S
Front Oncol; 2021; 11():744679. PubMed ID: 34595122
[TBL] [Abstract][Full Text] [Related]
24. Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter.
Wang G; Liu Y; Liu S; Lin Y; Hu C
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293504
[TBL] [Abstract][Full Text] [Related]
25. Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer.
Mulvey A; Muggeo-Bertin E; Berthold DR; Herrera FG
Front Immunol; 2022; 13():859785. PubMed ID: 35603186
[TBL] [Abstract][Full Text] [Related]
26. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
[TBL] [Abstract][Full Text] [Related]
27. Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances.
Movassaghi M; Chung R; Anderson CB; Stein M; Saenger Y; Faiena I
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638243
[TBL] [Abstract][Full Text] [Related]
28. Combining immunotherapies for the treatment of prostate cancer.
Redman JM; Gulley JL; Madan RA
Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
[TBL] [Abstract][Full Text] [Related]
29. Contemporaneous and upcoming trends in immunotherapy for prostate cancer: review.
Saleem S; Rashid AB; Shehzadi S; Mumtaz H; Saqib M; Bseiso A; Villasenor AV; Ahmed A; Sonia SN
Ann Med Surg (Lond); 2023 Aug; 85(8):4005-4014. PubMed ID: 37554896
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Inhibitors in Prostate Cancer.
Venkatachalam S; McFarland TR; Agarwal N; Swami U
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34063238
[TBL] [Abstract][Full Text] [Related]
31. Advancing therapies in metastatic castration-resistant prostate cancer.
Baciarello G; Gizzi M; Fizazi K
Expert Opin Pharmacother; 2018 Nov; 19(16):1797-1804. PubMed ID: 30311804
[TBL] [Abstract][Full Text] [Related]
32. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
33. New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer.
Lin M; Sun X; Lv L
Mol Ther Oncolytics; 2023 Jun; 29():91-106. PubMed ID: 37215386
[TBL] [Abstract][Full Text] [Related]
34. Potentiating prostate cancer immunotherapy with oncolytic viruses.
Lee P; Gujar S
Nat Rev Urol; 2018 Apr; 15(4):235-250. PubMed ID: 29434366
[TBL] [Abstract][Full Text] [Related]
35. Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives.
Rebuzzi SE; Rescigno P; Catalano F; Mollica V; Vogl UM; Marandino L; Massari F; Pereira Mestre R; Zanardi E; Signori A; Buti S; Bauckneht M; Gillessen S; Banna GL; Fornarini G
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267553
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
de Almeida DVP; Fong L; Rettig MB; Autio KA
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-18. PubMed ID: 32343604
[TBL] [Abstract][Full Text] [Related]
37. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
38. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
[TBL] [Abstract][Full Text] [Related]
39. Could Harnessing Natural Killer Cell Activity Be a Promising Therapy for Prostate Cancer?
Wu J
Crit Rev Immunol; 2021; 41(2):101-106. PubMed ID: 34348004
[TBL] [Abstract][Full Text] [Related]
40. The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy.
Salemme V; Centonze G; Cavallo F; Defilippi P; Conti L
Front Oncol; 2021; 11():610303. PubMed ID: 33777750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
